ML228 是一种有效的 HIF 信号通路激活剂，EC50 为 1 μM。ML228 可激活 HIF 以及下游 EGFR。

ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF.

ML228 represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications[1][2].

ML228 (injection; 1 μg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduces SCI secondary injury and promotes the recovery of neurological function[3].

1357171-62-0

C27H21N5

415.49

DMSO:30 mg/mL (72.2 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years